Development asset linked to Bioprojet in public FDA and regional records.
pharma · Eosinophilic esophagitis · Narcolepsy
Bioprojet
Bioprojet Pharma
Bioprojet drug portfolio — 19 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
9 rue Rameau, Paris, 75002, FR HQ
166 Employees
EMA registrant Type
Company details
- Status
- Public
- HQ
- 9 rue Rameau, Paris, 75002, FR
- Employees
- 166
- Programs
- 11
- Drugs
- 19
- Patents
- 9
Bioprojet pipeline
Portfolio lens on 19 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.
Bioprojet drug portfolio — 19 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.
Drug portfolio
-
-
Development asset linked to Bioprojet in public FDA and regional records.
-
Development asset linked to Bioprojet in public FDA and regional records. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
US regulatory status: approved. Mechanism: Unknown.
- Mechanism
- Unknown
-
Development asset linked to Bioprojet in public FDA and regional records.
-
Development asset linked to Bioprojet in public FDA and regional records.
-
Development asset linked to Bioprojet in public FDA and regional records.
-
dodecafluoropentane
Various (V08)Various (V08) compound in Bioprojet's portfolio. Mechanism: Ultrasound contrast agent.
- Mechanism
- Ultrasound contrast agent
-
epinephrine
Cardiovascular system (C01)US regulatory status: approved. Molecular target: Adrenergic receptor.
- Target
- Adrenergic receptor
- Mechanism
- Adrenergic receptor agonist
-
Development asset linked to Bioprojet in public FDA and regional records.
-
insulin aspart
Alimentary tract and metabolism (A10)US regulatory status: approved. Molecular target: Insulin receptor.
- Target
- Insulin receptor
- Mechanism
- Insulin receptor agonist
-
Development asset linked to Bioprojet in public FDA and regional records.
-
Development asset linked to Bioprojet in public FDA and regional records.
-
US regulatory status: approved. Molecular target: Sodium-dependent noradrenaline transporter.
- Target
- Sodium-dependent noradrenaline transporter
- Mechanism
- Norepinephrine transporter releasing agent
-
pitolisant
Nervous system (N07)US regulatory status: approved. Molecular target: Histamine H3 receptor.
- Target
- Histamine H3 receptor
- Mechanism
- Histamine H3 receptor inverse agonist
-
US regulatory status: approved. Molecular target: Histamine H3 receptor.
- Target
- Histamine H3 receptor
- Mechanism
- Histamine H3 receptor inverse agonist
-
Development asset linked to Bioprojet in public FDA and regional records.
-
Development asset linked to Bioprojet in public FDA and regional records.
-
Development asset linked to Bioprojet in public FDA and regional records.